Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      The authors comment on cholesterol, cardiovascular risk, statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and low-density lipoprotein cholesterol (LDL-C) lowering. Topics discussed include link between LDL-C and coronary heart disease (CHD) risk, information on the 2013 American College of Cardiology/American Heart Association cholesterol guidelines, and role of discovery science in developing more precise risk-prediction models.